Biopharmas love to break the news of an M&A deal with a splashy number. There’s the upfront fee, then milestones and other payments tacked on down the line. A new report suggests that commercial milestones currently represent as much as 40% of the so-called earnout potential for deals in the biopharma space—adding up to about […]
